GenomeDx to Present New Data on Genomic Testing for Bladder Cancer at American Urological Association Annual Meeting

SAN DIEGO, May 18, 2015 /PRNewswire/ -- GenomeDx Biosciences today announced that the company has identified a genomic signature that is predictive of metastasis in patients with muscle invasive bladder cancer. Researchers found that patients whose tumor RNA had a unique combination of 51 genes were more likely to have cancer spread to the lymph nodes.

The signature was identified using GenomeDx's Decipher^® platform to analyze over a million RNA markers present in each tumor sample. The Decipher platform has already generated a highly validated and commercially available test for predicting metastasis in men who have had prostate surgery. Data on this were presented today at the American Urological Association Annual Meeting in New Orleans by Dr. Roland Seiler of the Department of Urologic Sciences at the University of British Columbia.

"In patients with muscle invasive bladder cancer, the latest imaging techniques miss up to 25% of lymph node metastases. These patients have high rates of cancer recurrence and death," Dr. Seiler said. "More reliable methods to detect metastatic spread and therefore, identifying which patients are at highest risk for fatal outcome are greatly needed so that we can better direct intensified treatment and improve outcomes for these patients."

Doug Dolginow, M.D., Chief Executive Officer of GenomeDx, added: "With these data, we are taking a significant step in the growth of our Decipher platform beyond its existing applications in prostate cancer.  The Decipher platform has proven to be a powerful tool for identifying powerful genetic markers that are predictive of aggressive disease, and more accurate than existing tools at characterizing patient risk. We are dedicated to continued research to further validate the ability of the Decipher platform to bring a much needed diagnostic solution to patients suffering from bladder cancer."

The presentation, titled "Can Bladder Cancer Gene Expression Signatures be used to Predict Lymph Node Metastasis at the Time of Radical Cystectomy?" included data from an evaluation of 217 patients with muscle invasive bladder cancer. Data from 151 patients were used in selection of the 51-gene signature that could predict metastatic disease, and the test was validated in data from 66 patients. The genomic signature, also known as KNN51, was able to predict 82 percent of cases and outperformed two existing models for prediction of metastatic disease, Mitra2014 and Smith2011, (62 percent and 46 percent, respectively).

About Decipher^®

Decipher^® is a highly validated and commercially available platform that predicts cancer aggressiveness by looking for a unique genomic signature comprised of a validated series of biomarkers associated with metastatic disease. Adding truly unique information to the treatment decision-making process, Decipher generates a risk result that is completely independent and distinct from other clinical risk factors. Clinical studies from leading cancer centers published in over a dozen medical journals demonstrate that Decipher can accurately predict metastatic disease in patients with prostate cancer, which men may benefit from radiation therapy following prostate surgery, and can lead to significant cost-savings for healthcare systems. Decipher was developed in partnership with the Mayo Clinic.

The Decipher Prostate Cancer Classifier is covered by Medicare and multiple private insurance plans and is available to eligible US patients through their physicians.

Learn more at: www.DecipherTest.com  and follow Decipher on Twitter at @DecipherTest and on Facebook.

About GenomeDx Biosciences

GenomeDx Biosciences is focused on transforming cancer patient care by putting usable genomic information in the hands of patients and their physicians. GenomeDx is developing and commercializing Decipher^®, a highly validated genomic test for predicting metastatic disease in men with prostate cancer. In partnership with leading medical centers, the company has assembled the largest genomic catalogue of prostate cancer tumors in the world, representing billions of data points and more than 20 years of prostate cancer research expertise. Using advanced cloud-based bioinformatics, GenomeDx mines the genomic data to develop proprietary tests that address key clinical questions in cancer patient management. GenomeDx has partnered to share genomic data with leading clinician-scientists worldwide to collaboratively enrich the knowledge and understanding of urologic cancers for the goal of improving global cancer patient care. GenomeDx is based in San Diego, California and Vancouver, British Columbia.

Learn more at www.genomedx.com and follow us on Twitter at @GenomeDx, Facebook, LinkedIn and YouTube.

Media Contact:
Ian Stone
Canale Communications
619-849-5388
[email protected]

SOURCE GenomeDx Biosciences

Related Links

http://www.genomedx.com